Arthur C. Butcher Sells 14,010 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Boston Scientific Trading Down 0.8 %

Shares of Boston Scientific stock traded down $0.75 during trading hours on Monday, hitting $89.25. The company’s stock had a trading volume of 10,227,334 shares, compared to its average volume of 6,096,185. Boston Scientific Co. has a 12 month low of $53.93 and a 12 month high of $91.93. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market capitalization of $131.53 billion, a PE ratio of 74.38, a price-to-earnings-growth ratio of 2.65 and a beta of 0.79. The stock has a 50 day moving average of $85.99 and a 200 day moving average of $80.22.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the previous year, the firm posted $0.50 earnings per share. The business’s revenue was up 19.3% on a year-over-year basis. Analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on BSX shares. Evercore ISI boosted their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup increased their price target on Boston Scientific from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Bank of America lifted their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, Canaccord Genuity Group upped their price target on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Advisors Asset Management Inc. grew its stake in shares of Boston Scientific by 45.6% during the 1st quarter. Advisors Asset Management Inc. now owns 7,544 shares of the medical equipment provider’s stock worth $517,000 after acquiring an additional 2,361 shares in the last quarter. Silvercrest Asset Management Group LLC grew its position in Boston Scientific by 28.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 50,808 shares of the medical equipment provider’s stock valued at $3,480,000 after purchasing an additional 11,138 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $3,021,000. B. Riley Wealth Advisors Inc. boosted its stake in shares of Boston Scientific by 52.0% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 16,270 shares of the medical equipment provider’s stock worth $1,114,000 after buying an additional 5,564 shares during the last quarter. Finally, Meiji Yasuda Life Insurance Co grew its holdings in shares of Boston Scientific by 49.6% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 68,568 shares of the medical equipment provider’s stock valued at $4,696,000 after acquiring an additional 22,725 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.